Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Bryan

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
Free Radical Biology & Medicine|December 3, 2014
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2Adedamola Olayanju, Ian M Copple, Holly K Bryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
Free Radical Biology & Medicine|December 3, 2014
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2Adedamola Olayanju, Ian M Copple, Holly K Bryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners studyB J Monk, M F Brady, C Aghajanian, et al.
Pageof 15